Ausdal Financial Partners Inc. Buys 542 Shares of Johnson & Johnson (NYSE:JNJ)

Posted by on May 2nd, 2023

Ausdal Financial Partners Inc. lifted its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 4.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,599 shares of the company’s stock after acquiring an additional 542 shares during the quarter. Ausdal Financial Partners Inc.’s holdings in Johnson & Johnson were worth $2,226,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the stock. Glassy Mountain Advisors Inc. purchased a new stake in shares of Johnson & Johnson during the 4th quarter valued at about $35,000. Retirement Financial Solutions LLC purchased a new stake in Johnson & Johnson during the fourth quarter valued at approximately $40,000. TD Capital Management LLC bought a new position in Johnson & Johnson in the third quarter worth approximately $48,000. VitalStone Financial LLC purchased a new position in shares of Johnson & Johnson during the 4th quarter worth $52,000. Finally, Iron Horse Wealth Management LLC grew its position in shares of Johnson & Johnson by 112.8% during the 4th quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock valued at $53,000 after acquiring an additional 159 shares during the period. 67.94% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Down 0.1 %

JNJ opened at $163.60 on Tuesday. The firm has a 50-day simple moving average of $157.86 and a two-hundred day simple moving average of $167.04. Johnson & Johnson has a 52 week low of $150.11 and a 52 week high of $183.35. The company has a market capitalization of $426.06 billion, a PE ratio of 34.23, a price-to-earnings-growth ratio of 2.78 and a beta of 0.53. The company has a quick ratio of 0.77, a current ratio of 0.99 and a debt-to-equity ratio of 0.35.

Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings data on Tuesday, April 18th. The company reported $2.68 EPS for the quarter, beating the consensus estimate of $2.51 by $0.17. Johnson & Johnson had a net margin of 13.22% and a return on equity of 35.53%. The business had revenue of $24.75 billion during the quarter, compared to the consensus estimate of $23.61 billion. During the same quarter in the prior year, the firm earned $2.67 EPS. The business’s revenue was up 5.6% on a year-over-year basis. Analysts forecast that Johnson & Johnson will post 10.66 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd will be issued a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a dividend yield of 2.91%. The ex-dividend date of this dividend is Monday, May 22nd. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. Johnson & Johnson’s dividend payout ratio is 94.56%.

Insider Activity at Johnson & Johnson

In related news, insider James D. Swanson sold 1,062 shares of the stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the completion of the transaction, the insider now owns 9,215 shares of the company’s stock, valued at approximately $1,425,191.90. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.20% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

JNJ has been the subject of several analyst reports. Piper Sandler reduced their price objective on Johnson & Johnson from $55.00 to $52.00 in a research note on Monday, February 6th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, February 1st. Guggenheim initiated coverage on Johnson & Johnson in a research note on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 price objective for the company. SVB Leerink reduced their price objective on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research note on Friday, January 20th. Finally, Atlantic Securities reduced their price objective on Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating for the company in a research note on Wednesday, April 19th. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $173.00.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.

Featured Stories

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.